Skip to main content
. 2020 Aug 9;22(8):1513–1517. doi: 10.1111/jch.13978

TABLE 1.

Baseline demographic data of study participants

Demographics All patients in Hypertension clinic included in study N = 488 Patients with inter‐arm SBP difference ≥ 10 mmHg N = 81 (16.6%) Patients without inter‐arm SBP difference ≥ 10 mmHg N = 407 (83.4%) P‐value (Univariate regressionanalysis)
Males 236 (48.4%) 51 (63.0 %) 185 (45.5 %) .004
Age (y) 59.4 ± 16.8 63.3 ± 16.6 58.7 ± 16.8 .02
Body mass index (kg/m2) 31.0 ± 10.8 30.6 ± 6.8 31.1 ± 11.4 .67
Waist circumference (cm) 104.5 ± 17.2 103.8 ± 13.2 104.7 ± 17.8 .68
Smokers a 193 (39.9%) 25 (30.9%) 168 (41.7%) .07
Diabetes mellitus 149 (30.2%) 20 (25%) 129(31.2%) .38
Ischemic heart disease 68 (13.9%) 7 (8.6%) 61 (15.0%) .03
Peripheral arterial disease 47 (9.7%) 7 (8.6%) 40 (9.8%) .74
Cerebrovascular disease 52 (10.7%) 9 (11.1%) 43 (10.6%) .89
Atrial Fibrillation 23 (4.8%) 2 (2.5%) 21 (5.2%) .27
Congestive heart failure 18 (3.7%) 2 (2.5%) 16 (4.0%) .51
Creatinine (mmol) 95.9 ± 37.1 104.1 ± 41.4 94.2 ± 36.1 .05
LDL (mmol/L) 2.5 ± 1.1 2.6 ± 1.1 2.4 ± 1.1 .44
Protein: Creatinine ratio (>20 g/mol) 189 (41.5%) 35 (47.3 %) 154 (40.4%) .27
Hypertension meds: 2.8 ± 1.5 3.1 ± 1.3 2.8 ± 1.5 .09
Thiazide diuretic 253 (51.8%) 42 (51.9%) 211 (51.8%) .99
RAAS inhibitor 387 (78.5%) 64 (80.0%) 323 (78.2%) .91
Long‐acting CCB 310 (63.3%) 52 (64.2%) 258 (63.4%) .47
Alpha blocker 44 (9.0%) 10 (12.4%) 34 (8.4%) .27
K‐sparing diuretic 61 (12.5%) 9 (11.1%) 52 (12.8%) .66
Beta blocker 225 (46.1%) 47 (58.0%) 178 (43.8%) .05
Loop diuretic 37 (7.6%) 8 (9.9%) 29 (7.1%) .41
Other 64 (13.1%) 12 (14.8%) 52 (12.7%) .14
Lipid lowering therapy 219 (44.9%) 39 (48.2%) 180 (45.0%) .38

All figures as mean ± standard deviation or N (%).

Abbreviations: CCB, calcium channel blocker; DBP, diastolic blood pressure; LDL, low‐density lipoprotein; RAAS, renin‐angiotensin aldosterone system; SBP, systolic blood pressure.

a

Smokers = current or past smokers.